Telix paid $165 billion upfront primarily to secure ITM’s lead radioligand candidate ITM-11, which was recently rejected by ...

Barzolvolimab is a monoclonal antibody that binds to the receptor tyrosine kinase KIT and inhibits its activity. KIT is expressed in mast cells, the primary drivers of the inflammatory response in CSU ...

An investigational drug for the autoimmune condition Sjögren's disease has scored a phase 3 win for Amgen, marking a positive ...

Vertex has reported positive phase 2b data for its kidney disease prospect inaxaplin, boosting its efforts to expand beyond the population targeted in a pivotal trial. The phase 2 ...

Lexeo Therapeutics has agreed to acquire Mantle Therapeutics via an upfront payment of $8.3 million, aiming to expand its Friedreich’s ataxia (FA) portfolio while locking in three strategic ...

A phase 3 study of Otsuka and Ionis Pharmaceuticals’ amyotrophic lateral sclerosis (ALS) drug candidate has hit its primary endpoint, positioning the partners to talk to regulators about expedited ...

Boehringer Ingelheim and AI drug discovery company Envisagenics have agreed to a potential $1 billion multi-year pact that will task Boehringer with validating tumor-specific targets.  | Boehringer ...

Iambic Therapeutics is maintaining the momentum generated by its recent megaround and Big Pharma partnerships by gearing up ...